Loading...

Japan finances USD104 mn to help Vietnam build 10 hospitals

Image

10-Dec-15 The Japan International Cooperation Agency (JICA) has provided Vietnam with USD104 mn to finance the construction of ten hospitals. Costing USD120 mn, they are also funded by ministry and local budgets. The projects have been implemented since 2012, and are expected to ease overload at central level hospitals, and improve surgery, emergency and intensive care services. [image: JICA]

Read More

Here's why East Asia could be in big trouble

Image

09-Dec-15 Many countries in East Asia now have to worry about losing as much as 15% of their working-age population by 2040, according to the World Bank. It said aging population and low fertility rates are to blame. Policies such as encouraging women to work, reforming pension schemes and shifting focus from hospital care to primary care are being recommended. [image: Zhang Peng / LightRocket / Getty Images]

Read More

Korea, Vietnam to cooperate on telehealth and HIS

Image

03-Dec-15 Korea and Vietnam have vowed to enhance bilateral cooperation on healthcare and medical services, including developing telemedicine and exchanging technologies and data about hospital information systems (HIS). [image: Korea Net]

Read More

Japan’s generics market woos Indian firms

Image

16-Nov-15 Japan, with sales of USD115, accounts for 10% of the global pharma market, compared with 38% for the US and 21% for Europe. Lupin is the only Indian company in Japan's generics market. But now Sun Pharmaceuticals is planning to acquire Novartis' Japanese drug portfolio. Other Indian generics makers, including Dr Reddy’s and Glenmark, are also exploring options. [image: Bloomberg]

Read More

Hanmi Pharmaceutical signs Sanofi diabetes mega deal

Image

06-Nov-15 Korea's Hanmi Pharmaceutical has signed a contract with Sanofi to export USD4 bn worth of diabetes treatment technology, in a deal worth almost 30% of the value of the entire Korean pharma industry. Sanofi gains an exclusive worldwide license to develop and commercialize drugs based on the materials, except in Korea and China, where Hanmi retains co-commercialization rights. [image: Business Korea]

Read More
Share